<?xml version='1.0' encoding='utf-8'?>
<document id="28356904"><sentence text="Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review."><entity charOffset="31-61" id="DDI-PubMed.28356904.s1.e0" text="sodium zirconium cyclosilicate" /><entity charOffset="67-95" id="DDI-PubMed.28356904.s1.e1" text="sodium polystyrene sulfonate" /><pair ddi="false" e1="DDI-PubMed.28356904.s1.e0" e2="DDI-PubMed.28356904.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28356904.s1.e0" e2="DDI-PubMed.28356904.s1.e1" /></sentence><sentence text="Hyperkalemia is a serious medical condition that often manifests in patients with chronic kidney disease and heart failure" /><sentence text=" Renin-angiotensin-aldosterone system inhibitors are known to improve outcomes in these disease states but can also cause drug-induced hyperkalemia" /><sentence text=" New therapeutic options exist for managing hyperkalemia in these patients which warrant evidence-based evaluation" /><sentence text="" /><sentence text="The objective of this article was to review the efficacy and safety evidence for patiromer, sodium zirconium cyclosilicate (ZS9), and sodium polystyrene sulfonate (SPS) for the treatment of hyperkalemia"><entity charOffset="92-122" id="DDI-PubMed.28356904.s6.e0" text="sodium zirconium cyclosilicate" /><entity charOffset="124-127" id="DDI-PubMed.28356904.s6.e1" text="ZS9" /><entity charOffset="134-162" id="DDI-PubMed.28356904.s6.e2" text="sodium polystyrene sulfonate" /><entity charOffset="164-167" id="DDI-PubMed.28356904.s6.e3" text="SPS" /><pair ddi="false" e1="DDI-PubMed.28356904.s6.e0" e2="DDI-PubMed.28356904.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28356904.s6.e0" e2="DDI-PubMed.28356904.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28356904.s6.e0" e2="DDI-PubMed.28356904.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28356904.s6.e0" e2="DDI-PubMed.28356904.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28356904.s6.e1" e2="DDI-PubMed.28356904.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28356904.s6.e1" e2="DDI-PubMed.28356904.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28356904.s6.e1" e2="DDI-PubMed.28356904.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28356904.s6.e2" e2="DDI-PubMed.28356904.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28356904.s6.e2" e2="DDI-PubMed.28356904.s6.e3" /></sentence><sentence text="" /><sentence text="Current treatment options to enhance potassium excretion are SPS and loop diuretics, which are complicated by ambiguous efficacy and known toxicities"><entity charOffset="37-46" id="DDI-PubMed.28356904.s8.e0" text="potassium" /><entity charOffset="61-69" id="DDI-PubMed.28356904.s8.e1" text="SPS" /><pair ddi="false" e1="DDI-PubMed.28356904.s8.e0" e2="DDI-PubMed.28356904.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28356904.s8.e0" e2="DDI-PubMed.28356904.s8.e1" /></sentence><sentence text=" Patiromer and ZS9 are new agents designed to address this treatment gap"><entity charOffset="15-17" id="DDI-PubMed.28356904.s9.e0" text="ZS9" /></sentence><sentence text=" Both unabsorbable compounds bind potassium in the gastrointestinal (GI) tract to facilitate fecal excretion"><entity charOffset="34-43" id="DDI-PubMed.28356904.s10.e0" text="potassium" /></sentence><sentence text=" The capacity to bind other medications in the GI tract infers high drug-drug interaction potential, which has been demonstrated with patiromer but not yet investigated with ZS9 or SPS"><entity charOffset="174-182" id="DDI-PubMed.28356904.s11.e0" text="ZS9" /><entity charOffset="181-189" id="DDI-PubMed.28356904.s11.e1" text="SPS" /><pair ddi="false" e1="DDI-PubMed.28356904.s11.e0" e2="DDI-PubMed.28356904.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28356904.s11.e0" e2="DDI-PubMed.28356904.s11.e1" /></sentence><sentence text=" Phase II and III clinical trials of patiromer and ZS9 demonstrated clear evidence of a dose-dependent potassium-lowering effect and the ability to initiate, maintain, or titrate renin-angiotensin-aldosterone system inhibitors"><entity charOffset="103-112" id="DDI-PubMed.28356904.s12.e0" text="potassium" /><entity charOffset="51-59" id="DDI-PubMed.28356904.s12.e1" text="ZS9" /><pair ddi="false" e1="DDI-PubMed.28356904.s12.e1" e2="DDI-PubMed.28356904.s12.e1" /><pair ddi="false" e1="DDI-PubMed.28356904.s12.e1" e2="DDI-PubMed.28356904.s12.e0" /></sentence><sentence text=" There is limited evidence base for SPS: two small clinical trials indicated potassium reduction in chronic hyperkalemia"><entity charOffset="77-86" id="DDI-PubMed.28356904.s13.e0" text="potassium" /><entity charOffset="36-44" id="DDI-PubMed.28356904.s13.e1" text="SPS" /><pair ddi="false" e1="DDI-PubMed.28356904.s13.e1" e2="DDI-PubMed.28356904.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28356904.s13.e1" e2="DDI-PubMed.28356904.s13.e0" /></sentence><sentence text=" All agents may cause adverse GI effects, although they are less frequent with ZS9"><entity charOffset="79-81" id="DDI-PubMed.28356904.s14.e0" text="ZS9" /></sentence><sentence text=" Concerns remain for SPS to cause rare GI damage"><entity charOffset="21-23" id="DDI-PubMed.28356904.s15.e0" text="SPS" /></sentence><sentence text=" Electrolyte abnormalities occurred with patiromer and SPS, whereas urinary tract infections, edema, and corrected QT-interval prolongations were reported with ZS9"><entity charOffset="160-162" id="DDI-PubMed.28356904.s16.e0" text="ZS9" /><entity charOffset="55-57" id="DDI-PubMed.28356904.s16.e1" text="SPS" /><pair ddi="false" e1="DDI-PubMed.28356904.s16.e1" e2="DDI-PubMed.28356904.s16.e1" /><pair ddi="false" e1="DDI-PubMed.28356904.s16.e1" e2="DDI-PubMed.28356904.s16.e0" /></sentence><sentence text="" /><sentence text="Patiromer and ZS9 have improved upon the age-old standard SPS for the treatment of hyperkalemia"><entity charOffset="14-16" id="DDI-PubMed.28356904.s18.e0" text="ZS9" /><entity charOffset="58-60" id="DDI-PubMed.28356904.s18.e1" text="SPS" /><pair ddi="false" e1="DDI-PubMed.28356904.s18.e0" e2="DDI-PubMed.28356904.s18.e0" /><pair ddi="false" e1="DDI-PubMed.28356904.s18.e0" e2="DDI-PubMed.28356904.s18.e1" /></sentence><sentence text=" Additional research should focus on drug-drug interactions in patients on multiple medications, incidence of rare adverse events, and use in high-risk populations" /><sentence text="" /></document>